Translating AI-powered research into real-world cancer impact Apotek Joins NSF I-Corps Spark Special Cohort on AI/ML and Cancer Care Taipei | [November 12, 2025] — Vizuro is proud to announce that our Apotek platform  has been selected for the National Science Foundation (NSF) I-Corps Spark Cohort , beginning November 13, 2025 . This specialized program focuses on AI/ML-powered innovations in cancer research and care , empowering teams to translate cutting-edge science into

In the highly regulated and patient-centric world of pharmaceutical launches, gaining a rapid, nuanced understanding of public perception is no longer optional—it is a critical necessity. Social listening has evolved from a simple monitoring tool into a sophisticated intelligence engine, providing real-time data that directly informs safety monitoring, brand strategy, and commercial success.

Partnership with Professor Woei-Jer Chuang of NCKU to explore AI-powered discovery in protein drug design Vizuro Apotek AI Drug Discovery Platform x Industry-Academia Collaboration with NCKU Taipei | [October 27, 2025] — Vizuro LLC, a leading innovator in multimodal causal AI and generative AI for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) with Professor Woei-Jer Chuang, Ph.D., of the Department of Biochemistry and Molecular Biology, Na

Author: Chin-Lin Chen, Ph.D / Data Scientist at Vizuro Key Takeaway Drug discovery has entered the era of big data. Every year, thousands of disease and normal samples are profiled — yet one critical bottleneck remains: identifying clinically meaningful target–marker gene pairs for new drug development . The core value of Apotek Path is for this purpose: Identify disease-relevant targets → Causal modeling reveals mechanistic gene interactions tailored to your disease contex

Why causal AI is becoming pharma’s next strategic differentiator — from target validation to clinical trials and real-world evidence. Visualizing the Ladder of Causation in Pharma: from seeing correlations, to doing interventions, to imagining counterfactuals — the foundation of causal AI in drug discovery. Introduction: The Limits of Correlation in Drug Discovery Drug discovery today generates unprecedented volumes of data. Omics, imaging, electronic health records, and real

Partnership with Professor Tsong-Long Hwang of CGUST to explore AI-powered innovations in small molecule drug design Vizuro Apotek AI Drug Discovery Platform x Industry-Academia Collaboration with CGUST Taipei | [August 22, 2025] — Vizuro LLC, a leading innovator in multimodal causal AI  and generative AI  technology, announced today that it has signed a Memorandum of Understanding (MOU) with Tsong-Long Hwang, Ph.D., Vice President and Distinguished Professor at Chang Gung U

Author:  Ting-Yuan Wang, Solution Architect at Vizuro Realities of AI Implementation Over the past eight years, Vizuro has witnessed the rapid development and widespread application of AI across various industries. According to our client statistics, AI applications are most prevalent in the healthcare sector, accounting for 34%, followed by 25% in the pharmaceutical and life sciences industries, and 23% in manufacturing. Despite the enthusiasm and expectations surrounding AI

Fig 1.  Adaptyv Bio “Protein Design Competition Round2” Competition Overview Protein binding remains one of the most challenging aspects...

Vizuro and DCB announced the signing of a Memorandum of Understanding (MOU) Vizuro LLC, a leading innovator in multimodal causal AI...

We are thrilled to announce that Vizuro has joined NVIDIA Inception , a program that nurtures startups revolutionizing industries with...

Key Takeaways: The 2024 Nobel Prize in Chemistry was awarded for groundbreaking advancements in computational protein structure...